Precision medicine firms SOPHiA GENETICS and Servier launch joint ventures to boost oncology and rare neuro‑disorder R&D

SOPHiA GENETICS announced a joint venture with Memorial Sloan Kettering Cancer Center to create a precision‑medicine hub that will combine the hospital’s extensive clinical oncology data with SOPHiA’s AI platform. The partnership aims to accelerate the development of multimodal cancer diagnostics and therapies and make the resulting tools available to patients worldwide.

Separately, Servier and the non‑profit n‑Lorem Foundation entered a multi‑target collaboration to develop antisense‑oligonucleotide (ASO) treatments for rare neurodevelopmental disorders. n‑Lorem will supply its ASO technology to generate pre‑clinical candidates, which Servier will advance through clinical development, seeking to address conditions such as refractory epilepsy, genetic autism and leukodystrophies.